Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unexpected nasal changes in rats related to reflux after gavage dosing.
Damsch S, Eichenbaum G, Looszova A, Lammens L, Feyen B, Van den Bulck K, Knight E, Kelley M, Tonelli A. Damsch S, et al. Among authors: tonelli a. Toxicol Pathol. 2011 Feb;39(2):337-47. doi: 10.1177/0192623310388430. Epub 2010 Dec 14. Toxicol Pathol. 2011. PMID: 21422260
Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects.
Knight E, Eichenbaum G, Hillsamer V, Greway T, Tonelli A, Han-Hsu H, Zakszewski C, Yurkow E, Shukla U, End D, Louden C. Knight E, et al. Among authors: tonelli a. Int J Toxicol. 2011 Aug;30(4):385-404. doi: 10.1177/1091581811404708. Int J Toxicol. 2011. PMID: 21832269
Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC. Mamidi RN, et al. Among authors: tonelli ap. Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27. Cancer Chemother Pharmacol. 2010. PMID: 20661737
Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product.
Eichenbaum G, Johnson M, Kirkland D, O'Neill P, Stellar S, Bielawne J, DeWire R, Areia D, Bryant S, Weiner S, Desai-Krieger D, Guzzie-Peck P, Evans DC, Tonelli A. Eichenbaum G, et al. Among authors: tonelli a. Regul Toxicol Pharmacol. 2009 Oct;55(1):33-42. doi: 10.1016/j.yrtph.2009.05.018. Epub 2009 Jun 14. Regul Toxicol Pharmacol. 2009. PMID: 19500632 Review.
Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.
Gale DD, Landells LJ, Spina D, Miller AJ, Smith K, Nichols T, Rotshteyn Y, Tonelli A, Lacouture P, Burch RM, Page CP, O'Connor BJ. Gale DD, et al. Among authors: tonelli a. Br J Clin Pharmacol. 2002 Nov;54(5):478-84. doi: 10.1046/j.1365-2125.2002.01682.x. Br J Clin Pharmacol. 2002. PMID: 12445026 Free PMC article. Clinical Trial.
Pharmacokinetic comparison of leucovorin and levoleucovorin.
Zittoun J, Tonelli AP, Marquet J, De Gialluly E, Hancock C, Yacobi A, Johnson JB. Zittoun J, et al. Among authors: tonelli ap. Eur J Clin Pharmacol. 1993;44(6):569-73. doi: 10.1007/BF02440861. Eur J Clin Pharmacol. 1993. PMID: 8405015
329 results